The Rho Guanine Nucleotide Exchange Factor pipeline drugs market research report outlays comprehensive information on the Rho Guanine Nucleotide Exchange Factor targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Rho Guanine Nucleotide Exchange Factor pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Immunology, Ophthalmology, and Hematological Disorders which include the indications Oncology, Melanoma, Autoimmune Disorders, Rheumatoid Arthritis, Age Related Macular Degeneration, and Febrile Neutropenia. It also reviews key players involved in Rho Guanine Nucleotide Exchange Factor targeted therapeutics development with respective active and dormant or discontinued products.
The Rho Guanine Nucleotide Exchange Factor pipeline targets constitutes close to seven molecules. Out of which, approximately seven molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Filing rejected/ Withdrawn, Preclinical, and Discovery stages are 1, 2, and 4 respectively.
Rho Guanine Nucleotide Exchange Factor overview
Rho guanine nucleotide exchange factor (RhoGEF) is a protein that in humans is encoded by a gene ARHGEF. This protein is involved in cellular signaling pathways specifically in the activation of the Rho family of small GTPases. Guanine Nucleotide Exchange Factors (GEFs) facilitate the exchange of GDP (guanosine diphosphate) for GTP (guanosine triphosphate) on GTPases, such as Rho GTPases. The activation of Rho GTPases is crucial for various cellular processes, including the regulation of the cytoskeleton, cell migration, and cell cycle progression. RhoGEFs help “turn on” Rho GTPases by promoting the exchange of GDP for GTP, which activates these small GTPases and allows them to participate in signaling cascades that influence cell behavior. These processes are essential for normal cell function and are implicated in various physiological and pathological conditions.
For a complete picture of Rho Guanine Nucleotide Exchange Factor’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
